Drugs increase the risk of suicide in the elderly
DOI:
https://doi.org/10.12775/JEHS.2023.13.01.020Keywords
opioids, betablocker, levodopa, benzodiazepines, risk of suicide, the elderlyAbstract
The purpose of this paper is a systematic review of articles and research in the context of drugs used and suicide in elderly patients. Suicide in the elderly may be much more frequent than in the younger population. In addition to factors such as mental illness, dementia, deteriorating health, or problems with adapting to old age, the impact of chronic and reliever medications in this age group should also be considered. The greatest challenge of pharmacotherapy in the elderly is polypharmacy, drug interactions, different metabolism, pharmacokinetics and pharmacodynamics of the drugs used, as well as the side effects appearing in chronic therapy. In elderly patients, strong groups of drugs such as benzodiazepines and opioids are used extensively and sometimes too often. These drugs can cause addiction and overdose. Prescribing benzodiazepines alone carries a high risk of suicide. On the other hand, opioids often lead to addiction and abuse of these drugs, which may be associated with the development of respiratory depression. According to estimates by the Centers for Disease Control and Prevention (CDC), suicide accounts for approximately 7% of all opioid overdose deaths. Therapy should be carefully selected with regard to the use of other medications, drug interactions, and possible dependence and drug abuse by patients.The use of some classes of drugs in the elderly requires increased vigilance and control in the context of depression and episodes of suicide attempts. Drugs such as B blockers, digitalis glycosides, NSAIDs, opioids, ACEIs, calcium channel blockers, corticosteroids, diuretics, levodopa, and benzodiazepines can cause symptoms of depression. Older people are more susceptible to side effects of drugs, for example because of polypharmacy and the chronicity of treatment.
References
Stanley IH, Boffa JW, Rogers ML, Hom MA, Albanese BJ, Chu C, Capron DW, Schmidt NB, Joiner TE. Anxiety sensitivity and suicidal ideation/suicide risk: A meta-analysis. J Consult Clin Psychol. 2018 Nov;86(11):946-960. doi: 10.1037/ccp0000342. PMID: 30335426; PMCID: PMC6469498.
Official website of the World Health Organization https://www.who.int/news-room/fact-sheets/detail/suicide (accessed on 02/07/2022)
Lim JY, Lee DH. Characteristics of Drugs Ingested for Suicide Attempts in the Elderly. J Korean Med Sci. 2018 Mar 12;33(11):e86. doi: 10.3346/jkms.2018.33.e86. PMID: 29495136; PMCID: PMC5835585.
Rostami M, Younesi SJ, Mohammadi Shahboulaghi F, Malakouti SK, Foroughan M. Models of suicide in elderly: a protocol for a systematic review. BMJ Open. 2018 Oct 18;8(10):e022087. doi: 10.1136/bmjopen-2018-022087. PMID: 30341120; PMCID: PMC6196840.
Szücs A, Szanto K, Wright AGC, Dombrovski AY. Personality of late- and early-onset elderly suicide attempters. Int J Geriatr Psychiatry. 2020 Apr;35(4):384-395. doi: 10.1002/gps.5254. Epub 2020 Jan 7. PMID: 31894591; PMCID: PMC7291767.
Valera Ortín J, Lucerón Lucas-Torres MI. Factores relacionados con el suicidio en personas mayores: una revisión sistemática [Suicide related factors in the elderly: A systematic review.]. Rev Esp Salud Publica. 2021 Oct 8;95:e202110166. Spanish. PMID: 34620818.
Williams GO. Management of depression in the elderly. Prim Care. 1989 Jun;16(2):451-74. PMID: 2664841.
Patten SB, Love EJ. Drug-induced depression. Psychother Psychosom. 1997;66(2):63-73. doi: 10.1159/000289110. PMID: 9097332.
Schepis TS, Simoni-Wastila L, McCabe SE. Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults. Int J Geriatr Psychiatry. 2019 Jan;34(1):122-129. doi: 10.1002/gps.4999. Epub 2018 Oct 16. PMID: 30328160; PMCID: PMC6445380.
Cremaschi L, Grancini B, De Carlo V, Pozzoli S, Altamura AC, Dell'Osso B. Benzodiazepine ingestion as a way to die by suicide and related safety: the case of an elderly patient. Aging Clin Exp Res. 2019 Feb;31(2):287-289. doi: 10.1007/s40520-018-0966-1. Epub 2018 May 5. PMID: 29730844.
Dou C, Rebane J, Bardal S. Interventions to improve benzodiazepine tapering success in the elderly: a systematic review. Aging Ment Health. 2019 Apr;23(4):411-416. doi: 10.1080/13607863.2017.1423030. Epub 2018 Jan 16. PMID: 29336611.
Vukcević NP, Ercegović GV, Segrt Z, Djordjević S, Stosić JJ. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016 Mar;73(3):234-8. PMID: 27295906.
Olfson M, King M, Schoenbaum M. Benzodiazepina Stosować w Stanach Zjednoczonych. JAMA Psychiatria. 2015;72(2):136–142. doi:10.1001/jamapsychiatry.2014.1763
Boggs JM, Lindrooth RC, Battaglia C, Beck A, Ritzwoller DP, Ahmedani BK, Rossom RC, Lynch FL, Lu CY, Waitzfelder BE, Owen-Smith AA, Simon GE, Anderson HD. Association between suicide death and concordance with benzodiazepine treatment guidelines for anxiety and sleep disorders. Gen Hosp Psychiatry. 2020 Jan-Feb;62:21-27. doi: 10.1016/j.genhosppsych.2019.11.005. Epub 2019 Nov 17. PMID: 31765794; PMCID: PMC7001528.
Cho SE, Geem ZW, Na KS. Development of a Suicide Prediction Model for the Elderly Using Health Screening Data. Int J Environ Res Public Health. 2021 Sep 27;18(19):10150. doi: 10.3390/ijerph181910150. PMID: 34639457; PMCID: PMC8507921.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. PMID: 29536616; PMCID: PMC5947163.
Bourin M. Les problèmes posés par l'utilisation des benzodiazépines chez le patient âgé [The problems with the use of benzodiazepines in elderly patients]. Encephale. 2010 Sep;36(4):340-7. French. doi: 10.1016/j.encep.2010.04.016. Epub 2010 Jul 17. PMID: 20850606.
Azzam AAH, McDonald J, Lambert DG. Hot topics in opioid pharmacology: mixed and biased opioids. Br J Anaesth. 2019 Jun;122(6):e136-e145. doi: 10.1016/j.bja.2019.03.006. Epub 2019 Apr 19. PMID: 31010646.
Webster LR. Risk Factors for Opioid-Use Disorder and Overdose. Anesth Analg. 2017 Nov;125(5):1741-1748. doi: 10.1213/ANE.0000000000002496. PMID: 29049118.
Baldo BA. Toxicities of opioid analgesics: respiratory depression, histamine release, hemodynamic changes, hypersensitivity, serotonin toxicity. Arch Toxicol. 2021 Aug;95(8):2627-2642. doi: 10.1007/s00204-021-03068-2. Epub 2021 May 11. PMID: 33974096.
Pergolizzi J, Breve F, Magnusson P, Nalamasu R, LeQuang JAK, Varrassi G. Suicide by Opioid: Exploring the Intentionality of the Act. Cureus. 2021 Sep 18;13(9):e18084. doi: 10.7759/cureus.18084. PMID: 34692299
Vu Q, Beselman A, Monolakis J, Wang A, Rastegar D. Risk factors for opioid overdose among hospitalized patients. J Clin Pharm Ther. 2018 Dec;43(6):784-789. doi: 10.1111/jcpt.12701. Epub 2018 May 23. PMID: 29797421.
Sinyor M, Williams M, Gulati S, Schaffer A. An Observational Study of Suicide Deaths by Self-Poisoning with Opioids in Toronto (1998-2015). Can J Psychiatry. 2019 Aug;64(8):577-583. doi: 10.1177/0706743719838777. Epub 2019 Mar 24. PMID: 30905165
Oliva EM, Bowe T, Manhapra A, Kertesz S, Hah JM, Henderson P, Robinson A, Paik M, Sandbrink F, Gordon AJ, Trafton JA. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ. 2020 Mar 4;368:m283. doi: 10.1136/bmj.m283. PMID: 32131996
Karbakhsh M, Zandi NS. Pattern of poisoning in the elderly: An experience from Tehran. Clin Toxicol (Phila). 2008 Mar;46(3):211-7. doi: 10.1080/15563650701638982. PMID: 17906992
Olié E, Courtet P, Poulain V, Guillaume S, Ritchie K, Artero S. History of suicidal behaviour and analgesic use in community-dwelling elderly. Psychother Psychosom. 2013;82(5):341-3. doi: 10.1159/000350504. Epub 2013 Aug 9. PMID: 23942382.
Schepis TS, Simoni-Wastila L, McCabe SE. Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults. Int J Geriatr Psychiatry. 2019 Jan;34(1):122-129. doi: 10.1002/gps.4999. Epub 2018 Oct 16. PMID: 30328160
Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's Disease: Current Status and Future Developments. Curr Neuropharmacol. 2018;16(8):1239-1252. doi: 10.2174/1570159X15666170510143821. PMID: 28494719; PMCID: PMC6187751.
Ayobello A, Saway B, Greenage M. Attempted Suicide in a Parkinsonian Patient Treated with DBS of the VIM and High Dose Carbidopa-Levodopa. Case Rep Psychiatry. 2019 Mar 26;2019:2903762. doi: 10.1155/2019/2903762. PMID: 31032135; PMCID: PMC6457313.
Beitz JM. Parkinson's disease: a review. Front Biosci (Schol Ed). 2014 Jan 1;6(1):65-74. doi: 10.2741/s415. PMID: 24389262.
Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013 Aug;30(8):587-92. doi: 10.1007/s40266-013-0090-z. PMID: 23686524.
Camargo SM, Vuille-dit-Bille RN, Mariotta L, Ramadan T, Huggel K, Singer D, Götze O, Verrey F. The molecular mechanism of intestinal levodopa absorption and its possible implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther. 2014 Oct;351(1):114-23. doi: 10.1124/jpet.114.216317. Epub 2014 Jul 29. PMID: 25073474.
Boelens Keun JT, Arnoldussen IA, Vriend C, van de Rest O. Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review. Adv Nutr. 2021 Dec 1;12(6):2265-2287. doi: 10.1093/advances/nmab060. PMID: 34113965; PMCID: PMC8634393.
Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010 Jan;67(1):58-63. doi: 10.1001/archneurol.2009.294. PMID: 20065130.
Lim SY, Evans AH, Miyasaki JM. Impulse control and related disorders in Parkinson's disease: review. Ann N Y Acad Sci. 2008 Oct;1142:85-107. doi: 10.1196/annals.1444.006. PMID: 18990123.
Antonini A. Continuous dopaminergic stimulation--from theory to clinical practice. Parkinsonism Relat Disord. 2007 Sep;13 Suppl:S24-8. doi: 10.1016/j.parkreldis.2007.06.002. Epub 2007 Aug 16. PMID: 17702632.
Jost WH. Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration. Expert Opin Drug Saf. 2014 Apr;13(4):447-58. doi: 10.1517/14740338.2014.896336. Epub 2014 Mar 10. PMID: 24611456.
Vasta R, Nicoletti A, Mostile G, Dibilio V, Sciacca G, Contrafatto D, Cicero CE, Raciti L, Luca A, Zappia M. Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. PLoS One. 2017 Feb 16;12(2):e0172145. doi: 10.1371/journal.pone.0172145. PMID: 28207803; PMCID: PMC5312869.
Herrera J. Beta-blockers use for hypertension in the elderly. Cardiovasc Hematol Agents Med Chem. 2015;12(3):152-9. doi: 10.2174/1871525713666150310112759. PMID: 25761100.
McAinsh J, Cruickshank JM. Beta-blockers and central nervous system side effects. Pharmacol Ther. 1990;46:163–197. DOI: 10.1016/0163-7258(90)90092-g. PMID: 1969642
Drayer DE. Lipophilicity, hydrophilicity, and the central nervous system side effects of beta blockers. Pharmacotherapy. 1987;7: 87–91. DOI: 10.1002/j.1875-9114.1987.tb04029.x. PMID: 2891122
Neil-Dwyer G, Bartlett J, McAinsh J, et al. Beta-adrenoceptor blockers and the blood-brain barrier. Br J Clin Pharmacol. 1981;11: 549–553. DOI: 10.1111/j.1365-2125.1981.tb01169.x. PMID: 6115665
Waal HJ. Propranolol-induced depression. Br Med J. 1967;2:50. DOI: 10.1136/bmj.2.5543.50. PMID: 6021004
Luijendijk HJ, van den Berg JF, Hofman A, et al. β-Blockers and the risk of incident depression in the elderly. J Clin Psychopharmacol. 2011;31:45–50. DOI: 10.1097/JCP.0b013e31820482c4. PMID: 21192142
Patten SB. Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry. 1990;35:257–259. DOI: 10.1177/070674379003500312. PMID: 2140288
Gerstman BB, Jolson HM, Bauer M, et al. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol. 1996;49: 809–815. DOI: 10.1016/0895-4356(96)00017-0. PMID: 8691233
Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002;288:351–357. DOI: 10.1001/jama.288.3.351. PMID: 12117400
Conant J, Engler R, Janowsky D, et al. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. J Cardiovasc Pharmacol. 1989;13:656–661. PMID: 2471005
Thiessen BQ, Wallace SM, Blackburn JL, et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med. 1990;150:2286–2290. doi:10.1001/archinte.1990.00390220044009
Petrie WM, Maffucci RJ, Woosley RL. Propranolol and depression. Am J Psychiatry. 1982;139:92–94. DOI: 10.1176/ajp.139.1.92. PMID: 7055283
Callréus T, Agerskov Andersen U, Hallas J, et al. Cardiovascular drugs and the risk of suicide: a nested case-control study. Eur J Clin Pharmacol. 2007;63: 591–596. DOI: 10.1007/s00228-007-0293-5. PMID: 17468865
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Kornelia Kędziora-Kornatowska, Karolina Winiarek, Joanna Murawska, Karolina Mikut, Justyna Kwiecień, Aleksandra Wijata, Aysheh Al-Shaer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 524
Number of citations: 0